DRF 1042

Drug Profile

DRF 1042

Alternative Names: DRF-1042

Latest Information Update: 27 Jul 2010

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Mar 2010 DRF 1042 is still in phase I development in India
  • 03 Oct 2006 Dr. Reddy's Laboratories and ClinTec have entered into an agreement to co-develop DRF 1042 for the treatment of cancer
  • 28 Nov 2003 Data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top